Opinion|Videos|January 31, 2024
Assessing Treatment Response in Patients With Myelofibrosis
Response is assessed in patients starting a JAK inhibitor by monitoring symptoms on a severity scale, spleen size, blood counts, and overall patient impression of change, with the goal being reduction of symptoms and stabilization of blood counts to improve quality of life.
Advertisement
Episodes in this series
Advertisement
Related to this article
ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Advisory Panel Votes to Approve GRAIL Galleri MCED Screening Test
2
Psychedelic Medicine in Cancer Care: What Nursing Teams Need to Know
3
Oncology Nurse Shares Insights From Her Stage 4 Breast Cancer Journey
4
Reframing Nurse Fatigue as Systemic Safety Risk
5